Analysts predict that Mesoblast limited (NASDAQ:MESO) will report $1.05 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Mesoblast’s earnings, with estimates ranging from $1.00 million to $1.10 million. Mesoblast reported sales of $1.17 million in the same quarter last year, which indicates a negative year over year growth rate of 10.3%. The business is expected to announce its next quarterly earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Mesoblast will report full-year sales of $5.40 million for the current fiscal year, with estimates ranging from $3.00 million to $6.80 million. For the next year, analysts forecast that the company will post sales of $55.04 million, with estimates ranging from $10.00 million to $100.07 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Mesoblast.
Mesoblast (NASDAQ:MESO) last posted its earnings results on Wednesday, August 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $1.70 million during the quarter, compared to analyst estimates of $2.51 million. Mesoblast had a negative net margin of 203.51% and a negative return on equity of 10.48%.
A hedge fund recently bought a new stake in Mesoblast stock. Jane Street Group LLC purchased a new stake in shares of Mesoblast limited (NASDAQ:MESO) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,731 shares of the company’s stock, valued at approximately $102,000. Hedge funds and other institutional investors own 2.74% of the company’s stock.
Shares of NASDAQ:MESO traded up $0.19 during trading on Monday, reaching $7.58. The company had a trading volume of 121,888 shares, compared to its average volume of 49,690. The firm has a market cap of $762.78 million, a P/E ratio of -12.03 and a beta of 1.96. Mesoblast has a twelve month low of $4.74 and a twelve month high of $8.78. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.11.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: What are the risks of holding treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.